Protein biomarkers for subtyping breast cancer and implications for future research. (1st February 2018)

• Record Type: Journal Article
• Authors: Mueller, Claudius; Haymond, Amanda; Davis, Justin B.; Williams, Alexa; Espina, Virginia
• Is Part Of: Expert review of proteomics. Volume 15:Number 2(2018)
• Page Start: 131
• Page End: 152
• Publication Date: 2018-02-01
• Subjects: Basal-like -- biomarker -- breast cancer -- estrogen receptor -- HER2 -- mass spectrometry -- progesterone receptor -- reverse phase protein array -- signal transduction -- triple negative breast cancer; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2018.1421071
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction : Breast cancer subtypes are currently defined by a combination of morphologic, genomic, and proteomic characteristics. These subtypes provide a molecular portrait of the tumor that aids diagnosis, prognosis, and treatment escalation/de-escalation options. Gene expression signatures describing intrinsic breast cancer subtypes for predicting risk of recurrence have been rapidly adopted in the clinic. Despite the use of subtype classifications, many patients develop drug resistance, breast cancer recurrence, or therapy failure. Areas covered : This review provides a summary of immunohistochemistry, reverse phase protein array, mass spectrometry, and integrative studies that are revealing differences in biological functions within and between breast cancer subtypes. We conclude with a discussion of rigor and reproducibility for proteomic-based biomarker discovery. Expert commentary : Innovations in proteomics, including implementation of assay guidelines and standards, are facilitating refinement of breast cancer subtypes. Proteomic and phosphoproteomic information distinguish biologically functional subtypes, are predictive of recurrence, and indicate likelihood of drug resistance. Actionable, activated signal transduction pathways can now be quantified and characterized. Proteomic biomarker validation in large, well-designed studies should become a public health priority to capitalize on the wealth of information gleaned from the proteome.